Stay updated with breaking news from Everett Vokes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Today, the largest professional societies representing radiation oncology physicians in the United States announced a partnership with the goal of reforming rad
Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not make a difference in outcomes for treating patients with an advanced form of thyroid cancer that develops from thyroid follicular cells called differentiated thyroid cancer (DTC).
Patients who underwent sublobar resection and those who underwent more invasive lobectomy for early-stage non–small cell lung cancer (NSCLC) showed similar overall and disease-free survival outcomes in a recent study.
The traditional treatment for early-stage non-small cell lung cancer is a lobectomy, where a surgeon eradicates cancerous tissue by removing an entire lung lobe.
A lobectomy, in which the entire lung lobe is removed, is the standard medical procedure for treating early-stage non-small cell lung cancer.